Kalos Management, Inc. Verastem, Inc. Transaction History

Kalos Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.83 $2,550 - $4,575	-2,500 Reduced 10.75%	20,750 $23,000
Q1 2022 Jun 21, 2022	BUY	$1.06 - $2.1 $24,645 - $48,825	23,250 New	23,250 $32,000
Q4 2021 Feb 03, 2022	SELL	$2.05 - $3.2 $49,712 - $77,600	-24,250 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$2.54 - $4.07 $2,540 - $4,070	-1,000 Reduced 3.96%	24,250 $70,000
Q4 2020 Feb 11, 2021	SELL	$1.15 - $2.4 $4,600 - $9,600	-4,000 Reduced 13.68%	25,250 $53,000
Q4 2019 Feb 13, 2020	BUY	$0.86 - $1.44 $13,975 - $23,400	16,250 Added 125.0%	29,250 $39,000
Q3 2019 Nov 14, 2019	SELL	$1.21 - $1.59 $19,662 - $25,837	-16,250 Reduced 55.56%	13,000 $14,000
Q2 2019 Aug 14, 2019	BUY	$1.25 - $3.14 $36,562 - $91,845	29,250 New	29,250 $44,000
Q1 2019 May 15, 2019	SELL	$2.79 - $4.09 $81,607 - $119,632	-29,250 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$3.23 - $7.01 $21,802 - $47,317	6,750 Added 30.0%	29,250 $94,000
Q3 2018 Nov 14, 2018	BUY	$6.86 - $9.97 $154,350 - $224,325	22,500 New	22,500 $144,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.25B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.